Though intravitreal injection is commonly done in anti-VEGF therapy for age-related macular degeneration (Brown & Regillo, 2007), repeated injections carry a risk of inflammation or damage to the retina (Kiss et al, 2018). This evidence concerns the gene VEGFA and age-related macular degeneration.